Thomas Jefferson University

Jefferson Digital Commons
Department of Radiology Faculty Papers

Department of Radiology

12-1-2017

Silent Sentence Completion Shows Superiority Localizing
Wernicke's Area and Activation Patterns of Distinct Language
Paradigms Correlate with Genomics: Prospective Study.
Kamel El Salek
University of Texas MD Anderson Cancer Center

Islam S. Hassan
University of Texas MD Anderson Cancer Center

Aikaterini Kotrotsou
University of Texas MD Anderson Cancer Center
Follow this and additional works at: https://jdc.jefferson.edu/radiologyfp

Srishti
Abrol
Part of the Neurology Commons, Radiology Commons, and the Surgery Commons
University of Texas MD Anderson Cancer Center

Let us know how access to this document benefits you
Scott H. Faro

Temple University

Recommended Citation
Salek, Kamel El; Hassan, Islam S.; Kotrotsou, Aikaterini; Abrol, Srishti; Faro, Scott H.; Mohamed,
See
nextB.;
page
forPascal
additional
Feroze
Zinn,
O.; authors
Wei, Wei; Li, Nan; Kumar, Ashok J.; Weinberg, Jeffrey S.; Wefel, Jeffrey
S.; Kesler, Shelli R.; Liu, Ho-Ling Anthony; Hou, Ping; Stafford, R. Jason; Prabhu, Sujit; Sawaya,
Raymond; and Colen, Rivka R., "Silent Sentence Completion Shows Superiority Localizing
Wernicke's Area and Activation Patterns of Distinct Language Paradigms Correlate with
Genomics: Prospective Study." (2017). Department of Radiology Faculty Papers. Paper 51.
https://jdc.jefferson.edu/radiologyfp/51
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Department of Radiology Faculty Papers by an authorized administrator of the Jefferson
Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Authors
Kamel El Salek, Islam S. Hassan, Aikaterini Kotrotsou, Srishti Abrol, Scott H. Faro, Feroze B. Mohamed,
Pascal O. Zinn, Wei Wei, Nan Li, Ashok J. Kumar, Jeffrey S. Weinberg, Jeffrey S. Wefel, Shelli R. Kesler, HoLing Anthony Liu, Ping Hou, R. Jason Stafford, Sujit Prabhu, Raymond Sawaya, and Rivka R. Colen

This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/radiologyfp/51

www.nature.com/scientificreports

OPEN

Received: 16 June 2017
Accepted: 21 August 2017
Published: xx xx xxxx

Silent Sentence Completion Shows
Superiority Localizing Wernicke’s
Area and Activation Patterns of
Distinct Language Paradigms
Correlate with Genomics:
Prospective Study
Kamel El Salek1, Islam S. Hassan1, Aikaterini Kotrotsou 1,9, Srishti Abrol1, Scott H. Faro2,
Feroze B. Mohamed3, Pascal O. Zinn4, Wei Wei5, Nan Li5, Ashok J. Kumar1, Jeffrey S. Weinberg
Jeffrey S. Wefel7, Shelli R. Kesler 7, Ho-Ling Anthony Liu8, Ping Hou8, R. Jason Stafford8,
Sujit Prabhu6, Raymond Sawaya6 & Rivka R. Colen 1,9

6

,

Preoperative mapping of language areas using fMRI greatly depends on the paradigms used, as
different tasks harness distinct capabilities to activate speech processing areas. In this study, we
compared the ability of 3 covert speech paradigms: Silent Sentence Completion (SSC), category
naming (CAT) and verbal fluency (FAS), in localizing the Wernicke’s area and studied the association
between genomic markers and functional activation. Fifteen right-handed healthy volunteers and 35
mixed-handed patients were included. We focused on the anatomical areas of posterosuperior, middle
temporal and angular gyri corresponding to Wernicke’s area. Activity was deemed significant in a region
of interest if P < 0.05. Association between fMRI activation and genomic mutation status was obtained.
Results demonstrated SSC’s superiority at localizing Wernicke’s area. SSC demonstrated functional
activity in 100% of cancer patients and healthy volunteers; which was significantly higher than those for
FAS and CAT. Patients with 1p/19q non-co-deleted had higher extent of activation on SSC (P < 0.02).
Those with IDH-1 wild-type were more likely to show no activity on CAT (P < 0.05). SSC is a robust
paradigm for localizing Wernicke’s area, making it an important clinical tool for function-preserving
surgeries. We also found a correlation between tumor genomics and functional activation, which
deserves more comprehensive study.
Pre-surgical brain mapping has become part of the standard of care for patients with brain tumors1. One of the
most important tools for pre-surgical brain mapping is functional MRI (fMRI), which relies on blood oxygen
level-dependent (BOLD) signal to obtain rapid and repeated images of the brain while the patient performs
1
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Age, years

Sex

Handedness

SSC

FAS

CAT

57

F

R

Positive

Negative

Negative

45

M

R

Positive

Negative

Negative

50

F

R

Positive

Negative

Positive

28

F

R

Positive

Positive

Negative

23

M

R

Positive

Positive

Negative

25

M

R

Positive

Negative

Negative

27

M

R

Positive

Negative

Negative

29

M

R

Positive

Negative

Negative

31

M

R

Positive

Negative

Negative

33

M

R

Positive

Positive

Positive

50

F

R

Positive

Positive

NT

Positive

Negative

NT

42

F

R

39(a,b)

F

R

a)R temporal

Positive

Negative

Negative

b)L temporal

Positive

Negative

Negative

37

F

R

Positive

Positive

Negative

66

F

R

Positive

NT

Positive

Table 1. Demographic distribution of healthy volunteers and activity on SSC, FAS, and CAT. NT: Not tested.

special tasks2. To map cortical speech areas using fMRI, a well-tailored task is performed to ensure the activation of a specific eloquent region. A plethora of speech paradigms have been developed, with reliable results, for
mapping Broca’s area. However, these tasks have shown inconsistent results when mapping Wernicke’s area3,4.
Localization of Wernicke’s area is challenging due to the relative variation in its anatomical location5 and because
the complexity of speech processes extend beyond typical anatomical locations of Broca’s and Wernicke’s areas6.
Further, receptive speech processing has been postulated to be a function of intertwined neuronal mechanisms
that involve decision making, attention span, and working memory4,7. This explains why the commonly used
paradigms have shown variability and a lack of consistency for pre-surgical mapping purposes4,8,9.
To date, two studies, Zaca et al. and Ashtari et al.3,4, have evaluated silent sentence completion (SSC) in localizing areas of receptive speech processes. However, neither of these studies had a sufficiently large population
to generalize their results nor did they included brain tumor patients, whose performance can be impaired. The
importance of including brain cancer patients in any study evaluating fMRI paradigms is the fact that tumors
such as gliomas have been associated with various degrees of neurovascular uncoupling (NVU), which decreases
the BOLD contrast needed to detect active areas10. Thus, evaluating language tasks in such patients is important
for clinical implementation. Further, the aforementioned studies only included right-handed participants.
Recent studies have shown that there is a strong correlation between certain genetic markers and perfusion,
specifically relative cerebral blood volume (rCBV)11,12. Furthermore, certain key genomic markers have been
associated with changes in tumoral and peritumoral microenvironement11, which might impact the BOLD signal
and thus final fMRI result. Given that some of these markers carry important prognostic significance13, variations
in patterns of fMRI activation seen in cancer patients should be evaluated in the context of differential genomic
aberations.
Therefore, at its core, our study aims to determine the adequacy and robustness of SSC in localizing Wernicke’s
area compared to the most clinically used language tasks, i.e. CAT (category naming) and FAS (Word generation)4. Furthermore, we attempt to determine the association between functional activation patterns and signal intensity with the following key genetic markers: (i) tumor suppressor genes commonly mutated in gliomas
(tumor protein 53 (TP53), phosphatase and tensin homolog (PTEN)), (ii) epidermal growth factor receptor
(EGFR) which is associated with angiogenesis, (iii) genetic alterations that characterize low grade gliomas and
determine their subtype (isocitrate dehydrogenase 1 and 2 (IDH-1/2), 1p/19q co-deletion), (iv) downstream substrates and epigenetric events associated with treatment response in gliomas (S-100, and O6-methylguanine-DNA
methyltransferase (MGMT) promoter methylation).

Methods

Subjects. Healthy Participants. We obtained approval from the institutional review board of The University
of Texas MD Anderson Cancer Center (UTMDACC) (Houston, Texas) to perform this HIPAA-compliant prospective study (2011-0543-09), and all participants provided written informed consent prior to inclusion into
the study. All methods were performed in accordance with the approved guidelines. We recruited 15 healthy
participants between February 2014 and June 2015, all of whom were right-handed (7 males and 8 females; mean
age, 38.8 years; median age, 37; range, 23–66 years) (Table 1). Healthy participants were recruited from a database
of hospital volunteers. Subjects were initially contacted via email, a telephone screening was then performed to
ensure the following inclusion criteria: ≥18 years, native English speaker, no prior brain surgeries, no neuropsychological disorders, and no contraindications to MRI. All participants underwent SSC; however, two patients did
not undergo CAT and one did not undergo FAS due to technical difficulties at the time of scanning.
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Cancer Patients. Approval from UTMDACC institutional review board (PA15-0029) was obtained for this
HIPAA-compliant prospective study, and all participants provided written informed consent prior to inclusion
into the study. All methods were performed in accordance with the approved guidelines. All cancer patients
undergoing preoperative fMRI for brain mapping at UTMDACC from 8/1/14 to 12/31/2015 had SSC added to
their study. The cancer cohort included 35 subjects (22 males and 13 females; mean age, 42.5 years; median age,
43; range, 18–69 years). The cohort included 26 right-handed, 5 left-handed, and 4 ambidextrous individuals
(Table 2). Patients’ pathological disease types and grades are listed in Table 3. The inclusion criteria were as follows: 18 to 75 years of age, no contraindications to MRI, and evidence of a brain lesion on prior imaging. Ability
to perform tasks accurately was based on the neuropsychology team’s overall assessment of their cognitive profile
and behavioral observations. Neuropsychlogical testing was performed in clinic and directly before scanning.
Handedness was determined via the Edinburgh handedness inventory. Histopathological diagnoses and grades
were obtained from the available postoperative pathological reports14.

Imaging techniques.

Functional and structural images were acquired using a General Electric 3.0 Tesla
Discovery MR750 MR scanner (GE Healthcare, Waukesha, WI, USA) with a 32-channel birdcage head coil
(healthy volunteers) and 8-channel head coil (patients) and high-order shim. Functional images were acquired
using a T2*-weighted BOLD sequence (repetition time/echo time = 2000/30 msec, matrix size = 64 × 64,
field-of-view = 24 × 24 cm, slice thickness = 4 mm with no intersection gap, voxel size = 3.75 × 3.75 × 4 mm).
This imaging protocol allowed adequate coverage of the entire brain. A high-resolution 3D spoiled gradient echo
T1-weighted sequence was acquired for anatomic reference (repetition time/echo time = 6 msec/2 msec, matrix
size = 256 × 256, field-of-view = 24 × 24 cm, slice thickness = 1.2 mm, with no intersection gap, voxel size = 0.
94 × 0.94 × 1.2 mm).

Functional MRI paradigms.

Three covert language paradigms were used: SSC, FAS, and CAT. All paradigms were block designed, with alternating active and control blocks. Each paradigm had a duration of 4 min
and 20 seconds, with blocks alternating for 20 seconds each. All healthy participants and patients were exposed
to the language paradigms in the same order. Prior to scanning, both healthy participants and cancer patients
underwent practice trials as per our standard presurgical mapping guidelines to ensure that they can perform the
task and generate adequate number of words. During functional imaging acquisition, the paradigm was displayed
using an MR-compatible 32′ wide liquid crystal display, and oral instructions were provided via intercom.
Paradigm design. Silent Sentence Completion: Active block: The active block consisted of incomplete sentences
for which participants had to fill in a blank. Each sentence was presented for 5 seconds, and each active block
consisted of 4 different sentences.
Control block: Consisted of gibberish sentences with a format resembling the active block. The control block
also consisted of 4 sentences, each lasting for 5 seconds.
Word Generation and Category Naming: FAS active block: Participants were presented with a letter of the
alphabet and asked to generate words that started with the letter of alphabet shown. Each letter was presented for
the entire 20 seconds.
CAT active block: Participants were presented with a category (e.g., cities, types of food, colors etc.) and asked
to generate words related to the category shown. Each category was presented for the entire 20 seconds.
Control phase: In both FAS and CAT, participants were shown an image of an open hand and were asked to
flex and extend their hands bilaterally, which was then simplified to opposing the first and the second digits bilaterally (See attached supplementary material for complete paradigms).

Image Analysis. All image analyses were performed using the Dynasuite Neuro 3.0 workstation (In Vivo
Corporation, Gainesville, FL, USA). Image preprocessing included motion correction and spatial smoothing with
a 4-mm full width at half maximum Gaussian kernel; no slice timing correction, signal was not de-trended. All of
our analysis steps mimicked the clinical settings. The functional activation map was calculated using the correlation analysis between the task paradigm and the signal intensity time course of each voxel. A statistical threshold
was applied to optimize visualization of language area (Fig. 1). Once all of these steps were performed, an ROI
analysis was performed using the Dynasuite Neuro 3.0 workstation. First step included a manual thresholding
of activation maps with a corrected pbonf-value of P ≤ 0.05. P-values were adjusted for each case and for each
task separately in order to maximize the signal to noise ratio thus decrease the possibility of type II errors (false
positive), which is crucial in the setting of preoperative mapping. Localization of activity in the Wernicke’s area
was performed in-consensus by two experienced neuroradiologists (R.C.C., with 7 years of clinical experience
with fMRI; A.J.K, with 15 years of experience with fMRI) blinded to the specific language paradigm. Activation
in Wernicke’s area was defined as activation located in the temporal lobe, more specifically focused on the areas
of the posterior superior temporal, middle temporal, and angular gyri, which correlate with the conventional
anatomical location of centers of receptive speech processing. Activation was subsequently assessed on all 3 tasks
for the presence or absence of activity. Activity in that specific area was assessed by using the fMRI probe tool on
Dynasuite, which automatically incorporates that specific blob of activation into one homogenous ROI.
Statistical analysis. Language Task Activation Rates. Activation rate is defined as the percentage/propor-

tion of either cancer patients or healthy volunteers in which activation of Wernicke’s area was observed using
a specific task (i.e. SSC, FAS, and CAT.) The activation rates of Wernicke’s area with SSC, FAS, and CAT were
summarized using frequencies and percentages. The activation rate of SSC was reported with the mean, standard
deviation, and range. McNemar’s test was used to compare the activation rate between the tasks.
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Age,
years

Sex

Handedness

Tumor location

Histology/grade

SSC

FAS

36

F

R

L frontal

GBM/4

Positive

Negative Negative

p53, EGFR, PTEN IHC+

32

M

R

L parietal

Oligo-dendroglioma/3

Positive

Negative Negative

1p19q co-deletion, EGFR IHC+, IDH1 exon 4
mutation

CAT

Genetic markers

67

M

R

L frontal

GBM/4

Positive

Positive

Positive

EGFR IHC+

54

F

L

L parietal

GBM/4

Positive

Positive

Negative

EGFR IHC+

51

M

R

L insula

Anaplastic oligodendroglioma/3

Positive

Positive

Positive

1p/19q co-deletion, IDH1 (R132H) IHC+

53

M

R

L posterior temporal

GBM/4

Positive

Negative Negative

p53 IHC+, EGFR IHC+

18

F

R

L frontal

Mixed oligo-astrocytoma/3 Positive

Negative Negative

IDH1 (R132H) IHC+, EGFR, PTEN IHC+

69

F

R

L inferior temporal

GBM/4

Positive

Negative Negative

EGFR IHC+, MGMT promoter methylation

50

M

M

L frontal + temporal

GBM/4

Positive

Negative Negative

p53 IHC+

37

M

R

L temporal

Oligo-dendroglioma/3

Positive

Negative Negative

IDH1 exon 4 mutation, 1p/19q co-deletion

65

F

R

L parietal + angular gyri

GBM/4

Positive

Negative Negative

EGFR IHC+, PTEN loss of wild-type expression

45

M

R

L insula + frontal operculum

GBM/4

Positive

Negative Negative

None

19

M

R

L parietotemporal

GBM /4

Positive

Negative Negative

TP53 exon 8 mutation, IDH1 exon 4 mutation

33

M

R

L frontal, + L insula, + L
temporal

Oligo-dendroglioma/3

Positive

Negative Negative

1p/19q co-deletion, IDH1 (R132H) IHC+

18

F

R

R frontal + L frontal

Oligo-dendroglioma/2

Positive

Negative Negative

1p/19q co-deletion, IDH1 (R132H) IHC+

39

M

M

R insula, frontal, + temporal

Oligo-dendroglioma/2

Positive

Negative Negative

1p/19q co-deletion, IDH1 (R132H) IHC+

62

M

M

R frontal + insula

GBM/4

Positive

Negative Negative

p53 IHC+

R

L caudate nucleus, internal
capsule, + L temporal

GBM/4

Positive

Negative Negative

p53 IHC+

52

M

43

M

R

L frontal

Astrocytoma/2

Positive

Positive

43

M

L

R parietal

GBM/4

Positive

Negative Negative

p53, S-100 IHC+

51

F

R

L frontotemporal

GBM/4

Positive

Negative Negative

S100 IHC+

R

L frontal, insula, +anterior
temporal

GBM/4

Positive

Negative Negative

TP53 exon 7 mutation

51

F

Positive

IDH (R132H) IHC+, p53 IHC+

28

F

L

L frontal

Astrocytoma/3

Positive

Positive

Positive

IDH-1 R132H) IHC+, EGFR IHC+

50

M

R

R + L frontal

GBM/4

Positive

Positive

Positive

p53, PTEN, EGFR IHC+

31

F

R

Superior L temporal

Ganglioglioma/2

Positive

Negative Negative

None

62

M

L

L temporal

GBM/4

Positive

Negative Negative

PTEN, EGFR, P53 IHC+

54

M

R

R frontal + L temporal

GBM/4

Positive

Negative Negative

p53 IHC+

Astrocytoma/3

Positive

Negative Negative

IDH-1 (R132H) IHC+

Oligo-dendroglioma/2

Positive

Positive

1p/19q co-deletion,IDH-1 (R132H) IHC+

35

M

L

R occipitotemporal + bifrontal

25

F

R

R frontal

Positive

35

M

R

L posterior temporal

Oligo-dendroglioma

Positive

Positive

Negative

None

49

F

R

L temporal

Oligo-dendroglioma

Positive

Positive

Negative

1p/19q, IDH-2 p.515 G > A IHC+

18

M

R

L temporal

Astrocytoma

Positive

Negative Negative

p53 IHC+

R superior, middle, +inferior
Astrocytoma
frontal gyri

Positive

Positive

Positive

IDH1 (R132H) IHC+

Positive

33

M

R

48

M

R

L frontal

Diffuse glioma

Positive

Positive

32

F

M

L frontal

Astrocytoma

Positive

Negative Negative

IDH1 (R132H) IHC+, 1p/19q co-deletion
IDH1 (R132H) IHC+

Table 2. Patients’ clinical and demographic characteristics and findings on SSC, FAS, and CAT. R: right, L: left,
IHC: Immunohistochemistry, GBM: glioblastoma.

Task Activation Profile and Tumor Genomics. Genomic analysis was performed after biopsy and the status of
the following gene aberrations was collected: TP53 (exon 8 mutation and immunohistochemistry [IHC]+),
IDH1 (exon 4 mutation and IHC+ for arginine [R] to a histidine [H] substitution at position 132 [p. R132H]),
IDH2 (exon 4 mutation or IHC+), PTEN (IHC+ or loss of wild-type expression), EGFR (IHC+), S100 (IHC+),
1p/19q co-deletion, and MGMT promoter methylation11,15,16. Fisher’s exact test was used to assess the association
between detection status (defined as presence or absence of functional activity) and genomic marker status for
FAS and CAT. Wilcoxon rank sum test was used to assess the association between Extent of Activation (EOA)
(number of voxels activated/total number of voxels in the region of interest [ROI]) and genomic marker status for
SSC. All tests were 2-sided, and p-values of ≤0.05 were considered statistically significant. The statistical analysis
was carried out using SAS software version 9.4 (SAS Institute, Cary, NC).
Extent of Activation =

Scientific Reports | 7: 12054 | DOI:10.1038/s41598-017-11192-2

Number of voxels active
Total number of voxels in ROI

(1)

4

www.nature.com/scientificreports/
Grade
Pathological type

1

2

3

4

GBM

—

—

—

17

Oligo-dendroma

1

4

4

—

Astrocytoma

—

4

2

—

Mixed oligoastrocytoma

—

—

1

—

Glioma

—

2

—

—

Table 3. Pathological types and grades of tumors. GBM: glioblastoma.

Data availability. Most data generated or analysed during this study are included in the supplementary
material. Additional data can be proided by the corresponding author upon reasonable request.

Results

Silent Sentence Completion vs Word Generation and Category Naming.

Healthy
Participants. SSC showed 100% activation of Wernicke’s area in healthy volunteers (Table 1), with bilateral activation in 1 volunteer. FAS and CAT detected significantly fewer cases in the healthy volunteer group than did SSC
(p = 0.004 and 0.003 by McNemar’s test, respectively). For the same expected Wernicke’s region/ROI, FAS had a
positive activation rate of 31% (5 of 16 cases), whereas CAT had a positive activation rate of 19% (3 of 16 cases).
No significant difference was detected between FAS and CAT (p-value = 0.62 by McNemar’s test).
Patient Population. SSC had a 100% activation of Wernicke’s area in cancer patients (N = 35) (Table 2). For the
same expected Wernicke’s region, FAS and CAT detected significantly less cases in the cancer group than did SSC
(p FAS and CAT detected significantly fewer cases in the healthy volunteer group than did SSC (p < 0.0001 by
McNemar’s test). FAS had a positive activation rate of 28.6% (10 of 35 cases), and CAT had a rate of 22.9% (8 of 35
cases) (Fig. 2). No significant difference was detected between FAS and CAT (p-value = 0.08 by McNemar’s test).

Genomic markers and functional activation.

There were statistically significant associations found
between rates of functional activation and EOA in an ROI with genomic marker status in our cancer patients
(Supplementary Tables 1–4). With regards to rates of functional activation, we found a significant association
between IDH1 mutation status and presence of functional activity on CAT. Out of our 35 patients, 15 (43%)
patients had IDH1 mutation. Patients with IDH1 wild-type were more likely to be classified as negative on CAT;
a higher percentage of patients with IDH1 wild-type tumors showed no activation (90.48% versus 9.52%) versus those with IDH1 mutation (60% versus 40%) (p-value = 0.05) (Table 4). However, this association did not
replicate in the glioma histopathological subgroup analysis due to reduced sample size and the resulting smaller
testing power. Functional activation was more common in patients with IDH1 mutated versus IDH1 wild-type
tumors (40% versus 9.52%) (p-value = 0.05) (Table 4). This indicates that patients with IDH1 mutated tumors
have higher activation rates in Wernicke’s area. The latter trend was also seen on FAS. On the other hand, SSC
showed constant activation in the Wernicke’s area regardless of IDH1 mutation status or other genomic markers
(Supplementary Table 5).
Relating to EOA, there was a statistically significant association between SSC and EOA in patients with 1p/19q
co-deletion. In our cohort, 74% (26/35) of patients had 1p/19q co-deletion. Patients without 1p/19q co-deletion
showed a higher median EOA compared with 1p/19q co-deletion (71% versus 42%; p-value = 0.02) (Table 5).
This finding indicates that patients with 1p/19q co-deletion have a lower fraction of voxels activated within an
ROI (milder level of activation) of Wernicke’s area. This association was not replicated after stratifying patients
into their respective histopathological subgroups. No other significant associations were found between the other
genomic markers and functional activation rate or EOA (Supplementary Tables 5 and 6).

Discussion

Our results clearly demonstrate that SSC is superior to FAS and CAT at localizing Wernicke’s area, with a significantly higher activation rate in both cancer patients and controls. Further, SSC showed those activation rates
in Wernicke’s area across various types of gliomas in different anatomical locations, reflecting its efficacy and
consistency. Our results also demonstrate that the presence of functional activation on SCC was constant and not
affected by genomic mutation status. However, patients with 1p/19q co-deletion showed less EOA in Wernicke’s
area on SSC, and patients with IDH1 mutation showed higher magnitude of signal intensity on CAT.
Given that our results revealed SSC to be a far more effective task in engaging Wernicke’s area and in the
absence of any other receptive language paradigm that has been clinically tested on both healthy and brain
tumor patients, we are confident that SSC can potentially be the task of choice when mapping receptive speech
areas. As a reading comprehension task, SSC can activate areas in the posterior temporal cortex that pertain
to language processing more comprehensively than all other verbal fluency or auditory word discrimination
tasks3. Sentence completion requires simultaneous reading comprehension, semantic processing, and word
retrieval, all of which demand neuronal processing in the superior, middle, and inferior temporal lobes3,17,18.
Compared to the motor control phase of FAS and CAT, SSC’s control phase allowed the subtraction of any
visual or semantic processing, thus increase the signal-to-noise ratio. As a covert task, SSC minimizes motion
artifacts19, which usually contributes to increased signal noise, even after the deployment of image registration algorithms20. SSC is an adequate localizing and lateralizing task. In our study, lateralization was assessed
Scientific Reports | 7: 12054 | DOI:10.1038/s41598-017-11192-2
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Figure 1. 3D reconstruction of fMRI activation maps in a patient with left temporal lobe astrocytoma on SSC
(Orange), FAS (Blue), and CAT (Violet).

Figure 2. ROI (yellow outline) at the location of Wernicke’s area showing activity on SSC, FAS, and CAT, from
left to right, respectively in a patient with left temporal glioblastoma. SSC showed 8 active voxels (red); no active
voxels detected on FAS and CAT.
IDH-1 Mutation status and Wernicke’s activation on CAT
Activation on CAT
Negative

Positive

IDH-1 Mutation

N

%

N

%

Absent

19

90.48

2

9.52

Present

9

60.00

6

40.00

P-value (CAT)

0.05

Table 4. Genomic markers and functional activation.

qualitatively by the presence or absence of activation in the contralateral hemisphere, reproducing the clinical
setting in which radiologists rely on their clinical judgment and expertise to determine lateralization. Including
right-handed, left-handed, and ambidextrous patients ensured enough variation to confidently conclude that
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ROI signal intensity on SSC and 1p/19q mutation status
1p/19q co-deletion status N

Mean

SD

Min

Median

Max

Absent

27

67%

22%

33%

71%

100%

Present

9

47%

13%

33%

42%

75%

P-value
0.02

Table 5. Genomic markers and functional activation.

SSC is a robust lateralizing task. Bilateral activation, which was seen in one of the healthy participants, could
be explained by the role that the right homologue of Wernicke’s area plays in the processing of subordinate
meanings of words in healthy young individuals21.
As previously discussed, we found statistically significant associations between certain key genomic markers and
functional activation. Patients with IDH1 mutation had higher activation rates of Wernicke’s area on CAT. Patients
with 1p/19q non-codeletion demonstrated a higher magnitude of median and mean EOA on SSC. It is known that
certain genetic aberrations affect the tumor microenvironment such as cerebral blood flow and peri-tumoral angiogenesis11, which can alter patterns of functional activity. In previous studies done on murine models, IDH1 mutant
mice exhibited an altered biochemical profile, which lead to a downstream increase in hypoxia inducible factor-1
α and its target genes including vascular endothelial growth factor22,23. This pattern of increased angiogenesis was
also seen in a study by Kickingereder et al. (2015), who demonstrated that an increase in rCBV values increased the
likelihood of an IDH mutant tumor24. In turn, this altered state of angiogenesis and cerebral perfusion could affect
the BOLD signal and eventually translate to higher activation rates, which is concordant with our finding. Clinically,
this also suggests that the tumoral genomic profile, if known, might eventually dictate the use of a specific batch of
language tasks that have been shown to be more effective in activating specific cortical areas. On the other hand,
even though there has been no direct correlation between 1p/19q co-deletion and tumoral angiogenesis, it has been
associated with a higher relative CBV values25. This might be due decreased activation volumes because of NVU; a
phenomenon that is dependent on tumor grade and type and on the distance to the eloquent cortex26. These findings
highlight the potential of implementing genomic agnostic language paradigms and tailoring examinations according
to a patient’s genomic profile, particularly in an era where the effectiveness of surgical and chemotheraputic interventions in the treatment of gliomas are influenced by a tumor’s genomic profile27,28.
This study included a relatively large number of healthy individuals and cancer patients, which provided two
advantages: an adequate control group and robust statistical power. In addition, including healthy participants
and cancer patients with various types of gliomas ensured the heterogeneity of our study population to account
for most of the possible confounders that accompany an fMRI study and more importantly, account for the varying degrees of NVU across different types and grades of glioma10. The absence of correlation with direct brain
cortical stimulation, which remains the gold standard for brain mapping29, is the main limitation of this study. We
are currently in the process of conducting a study that aims to validate SSC via DCS and radiomic texture analysis.
Another limitation stems from the controversy surrounding the classic anatomical model of language representation that describes Wernicke’s area as a discrete anatomical location, as opposed to the neurocognitive models,
which describe receptive language centers as a complex interconnected network that is not limited to any specific
location3,30. However, the aim of this study was primarily to show that SSC is, in fact, robust for the identification
of important cortical areas of receptive language processing, which is necessary for function-preserving surgery,
rather than to delineate the relationship between different areas of language processing31. Furthermore, in this
study we compared SSC to CAT and FAS, which are the tasks most frequently used in the clinic for language
mapping; other tasks that require language comprehension have been recently proposed, thus further research
comparing SSC with these tasks is warranted.
In conclusion, SCC is a highly effective paradigm for activating Wernicke’s area. The paradigm is superior to
the widely used FAS and CAT paradigms, providing a reliable clinical tool for preoperative brain mapping. In
addition, there seems to be an association between tumor genomics and patterns of functional activity. This might
translate as variations in task-related activation rates and EOA seen in eloquent cortex, an aspect that is extremely
valuable in the setting of preoperative mapping and should be investigated further.
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